OCS

Oculis Holding AG

7.64

Nov 13 • 3:59 PM ET +0.14 (1.87%)

7.69

Aftermarket • 5:00 PM ET +0.05 (0.65%)

Healthcare Biotechnology Switzerland Small NASD

Peers: EYPT OCUL KOD TARS ALDX LENZ REGN HROW BLCO GKOS

| Held by: SBIO GWX ONEQ BBC GLCR

Scroll to Statements

Index	-
Market Cap	471.63M
Enterprise Value	223.11M
Income	-101.30M
Sales	0.00M
Book/sh	4.04
Cash/sh	4.08
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	60
IPO	May 18, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.89
P/C	1.87
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	10.41
Current Ratio	10.41
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	-1.72
EPS next Y	-1.89
EPS next Q	-0.51
EPS this Y	23.46%
EPS next Y	-8.99%
EPS next 5Y	5.12%
EPS past 3/5Y	-26.82% -
Sales past 3/5Y	- -
EPS Y/Y TTM	31.72%
Sales Y/Y TTM	-
EPS Q/Q	9.72%
Sales Q/Q	-
Earnings	Nov 03 AMC
EPS/Sales Surpr.	23.35% -97.88%

Insider Own	23.77%
Insider Trans	0.00%
Inst Own	28.64%
Inst Trans	8.09%
ROA	-41.42%
ROE	-48.92%
ROIC	-40.14%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-0.77%
SMA50	-12.59%
SMA200	-57.24%
Trades

Shs Outstand	61.92M
Shs Float	47.06M
Short Float	3.37%
Short Ratio	5.94
Short Interest	1.58M
52W High	34.47 -77.84%
52W Low	6.78 12.68%
Volatility	6.46% 7.57%
ATR (14)	0.57
RSI (14)	44.34
Beta	0.30
Rel Volume	0.69
Avg Volume	266.63K
Volume	183,989

Perf Week	2.00%
Perf Month	3.24%
Perf Quarter	-41.86%
Perf Half Y	-74.78%
Perf YTD	-61.74%
Perf Year	-60.39%
Perf 3Y	-22.04%
Perf 5Y	-21.48%
Perf 10Y	-
Recom	1.27
Target Price	36.66
Prev Close	7.50
Price	7.64
Change %	1.87%

Consensus

Strong Buy

Avg. Price Target

$36.66

Implied Upside

+379.8%

Analysts10incl. previous ratings

Rating Distribution10 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
May 21, 2026	Initiated	GGuggenheim	Buy	$75	+881.7%
Dec 19, 2025	Initiated	JJP Morgan	Overweight	$38	+397.4%
Aug 27, 2025	Initiated	NNeedham	Buy	$36	+371.2%
Dec 05, 2023	Initiated	CChardan Capital Markets	Buy	$30	+292.7%
Oct 05, 2023	Initiated	SStifel	Buy	$35	+358.1%
Jun 14, 2023	Initiated	BBofA Securities	Buy	$22	+188.0%
Jun 12, 2023	Initiated	HH.C. Wainwright	Buy	$28	+266.5%
Jun 08, 2023	Initiated	RRobert W. Baird	Outperform	$58	+659.2%
May 10, 2023	Initiated	PPareto	Buy	$23	+201.0%
Apr 28, 2023	Initiated	WWedbush	Outperform	$27	+253.4%

Nov-13-26 04:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
Nov-09-26 02:00AM	Oculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development Pipeline (GlobeNewswire)
Nov-03-26 04:05PM	Oculis Reports Q3 2026 Financial Results and Builds Momentum Toward Multiple Upcoming Pipeline Catalysts (GlobeNewswire)
Nov-02-26 03:18AM	Oculis Appoints Experienced Life Sciences Leader Bjorn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to Advance Neurology Innovation (GlobeNewswire) -6.66%
Oct-29-26 05:39AM	Oculis to Feature Privosegtor's Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit (GlobeNewswire)
02:00AM	Loading…
Oct-22-26 02:00AM	Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor's Neuroprotective Potential in Optic Neuritis (GlobeNewswire)
Oct-20-26 02:00AM	Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting (GlobeNewswire)
Oct-19-26 02:00AM	Oculis lýkur slembiroðun i PREDICT-1 skraningarrannsokninni a Licaminlimab við TNFR1-miðluðum augnþurrki (GlobeNewswire)
02:00AM	Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease (GlobeNewswire)
Oct-08-26 04:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
Oct-07-26 02:00AM	Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day (GlobeNewswire)
Oct-01-26 02:00AM	Oculis Joins the National Multiple Sclerosis Society's Campaign to End MS (GlobeNewswire) -6.21%
Sep-30-26 05:32PM	Oculis Announces Resignation of Lionel Carnot from Board of Directors (GlobeNewswire)
Sep-17-26 04:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
Aug-24-26 04:00AM	First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis (GlobeNewswire)
04:05PM	Loading…
Aug-14-26 04:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
Aug-10-26 03:30AM	Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis' Position as an Emerging Leading Neuro-Ophthalmology Company (GlobeNewswire)
Aug-06-26 04:05PM	Oculis Reports Q2 2026 Financial Results and Provides Company Update (GlobeNewswire)
Aug-05-26 09:33AM	Earnings To Watch: Oculis Holding AG (OCS) Reports Q2 2026 Result (GuruFocus.com)
Aug-03-26 04:00AM	Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses (GlobeNewswire) +5.13%
Jul-08-26 04:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
Jul-02-26 04:00AM	Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference (GlobeNewswire)
Jun-15-26 04:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
Jun-11-26 04:00AM	Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026 (GlobeNewswire)
Jun-10-26 04:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
Jun-09-26 03:21PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
04:00AM	Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease (GlobeNewswire)
Jun-08-26 03:25PM	Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference (GlobeNewswire)
May-29-26 04:18PM	OCS Stock Drops Over 23% Eye Drop Trial For Diabetic Vision Loss Misses Target (Stocktwits) -23.42% -36.09%
04:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
03:06PM	Loading…
03:06PM	Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema (GlobeNewswire)
May-28-26 04:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
May-21-26 09:40AM	Etsy upgraded, ZoomInfo downgraded: Wall Street's top analyst calls (The Fly) +11.07%
May-15-26 04:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire) -7.33%
May-14-26 04:05PM	Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors (GlobeNewswire)
May-11-26 04:07PM	Oculis Reports Q1 2026 Financial Results and Provides Company Update (GlobeNewswire) -6.86%
May-07-26 05:00AM	Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial (GlobeNewswire) +5.10%
May-06-26 09:25AM	Oculis Holding AG (OCS) Q1 2026 Earnings Report Preview: What To Expect (GuruFocus.com) +6.59%
May-05-26 04:00AM	Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting (GlobeNewswire)
May-01-26 04:00AM	Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting (GlobeNewswire)
Apr-21-26 04:05PM	Oculis Publishes Invitation to the Annual General Meeting (GlobeNewswire)
Apr-20-26 04:00AM	Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema (GlobeNewswire)
Apr-08-26 04:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
Apr-07-26 04:00AM	Oculis to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-31-26 05:00AM	Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First-in-Class Neuroprotective Candidate for Optic Neuritis (GlobeNewswire) +8.31%
Mar-27-26 05:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
Mar-16-26 05:00AM	Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting (GlobeNewswire)
03:24AM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
Mar-13-26 05:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire) -6.15%
Mar-11-26 05:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
Mar-06-26 04:01PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
Mar-05-26 04:00AM	Oculis to Participate in Upcoming Investor Conferences (GlobeNewswire)
04:00AM	Oculis Publishes 2025 Consolidated Financial Statements (GlobeNewswire)
Mar-04-26 04:15PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
Mar-03-26 05:35PM	Oculis Holding AG (OCS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update (GlobeNewswire)
Mar-02-26 07:17AM	Earnings To Watch: Oculis Holding AG (OCS) Reports Q4 2025 Result (GuruFocus.com)
Feb-27-26 04:15PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
Feb-18-26 04:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated (GlobeNewswire)
Feb-17-26 04:00AM	Oculis Appoints Katie Kazem as Chief Legal Officer (GlobeNewswire)
Jan-09-26 06:04AM	J.P. Morgan Bangs the Drum on These 2 Strong Buy Stocks (TipRanks)
Jan-08-26 04:00AM	Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference (GlobeNewswire) +5.05%
Jan-06-26 04:34PM	S&P 500 and Dow Rally to Record Highs as Tech Stocks Surge (Barchart) +5.82%
04:00AM	Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis (GlobeNewswire)
Jan-05-26 04:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
Dec-09-25 04:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
Dec-08-25 09:55AM	Wall Street Analysts Predict a 106.04% Upside in Oculis Holding AG (OCS): Here's What You Should Know (Zacks) -5.03%
Dec-03-25 04:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
12:00PM	Oculis Holding AG (OCS) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-28-25 04:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
Nov-18-25 04:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
Nov-10-25 05:15PM	Oculis Holding AG (OCS) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
04:05PM	Oculis Reports Q3 2025 Financial Results and Provides Company Update (GlobeNewswire)
Nov-06-25 09:10AM	Vericel Corporation (VCEL) Q3 Earnings and Revenues Top Estimates (Zacks)
Nov-05-25 07:41AM	Oculis Holding AG (OCS) Q3 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
04:00AM	Oculis to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Oct-30-25 04:30AM	Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development (GlobeNewswire) -6.77%
Oct-24-25 04:38AM	Harmony Biosciences (HRMY) Moves 12.7% Higher: Will This Strength Last? (Zacks)
Oct-14-25 04:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
04:00AM	Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025 (GlobeNewswire)
Oct-10-25 08:54AM	Oculis Holding AG (OCS) Soars 6.3%: Is Further Upside Left in the Stock? (Zacks)
Oct-08-25 04:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire) +6.34%
Oct-06-25 04:07AM	Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy (GlobeNewswire) +5.61%
Sep-26-25 04:05PM	Oculis Publishes Notification of Transactions by Person Discharging Managerial Responsibilities (GlobeNewswire)
Sep-23-25 10:24AM	Strength Seen in Oculis Holding AG (OCS): Can Its 6.7% Jump Turn into More Strength? (Zacks)
Sep-22-25 04:00AM	Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS (GlobeNewswire) +6.68%
Sep-09-25 04:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
Sep-04-25 01:00PM	Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025 (GlobeNewswire)
Sep-03-25 04:05PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
Sep-01-25 04:00AM	Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences (GlobeNewswire)
Aug-28-25 04:00AM	Oculis to Participate in Upcoming September Investor Conferences (GlobeNewswire) -5.63%
Aug-25-25 04:00AM	Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical Advisors (GlobeNewswire)
Aug-21-25 05:15PM	Oculis Holding AG (OCS) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
04:05PM	Oculis Reports Q2 2025 Financial Results and Provides Company Update (GlobeNewswire)
Aug-14-25 07:20AM	Adherex Technologies Inc. (FENC) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Aug-13-25 09:25AM	Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Aug-12-25 05:30PM	Generation Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:00AM	Oculis to Participate in Upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference (GlobeNewswire)
Aug-07-25 05:25PM	CytomX Therapeutics (CTMX) Reports Break-Even Earnings for Q2 (Zacks)
Aug-06-25 09:50AM	YmAbs Therapeutics (YMAB) Surges 103.3%: Is This an Indication of Further Gains? (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sherif Riad	Officer	Mar 09 '26	Proposed Sale	26.40	25,000	660,000		Mar 09 04:08 PM

Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The firm's pipeline includes multiple product candidates in development such as, OCS-01, a topical retinal candidate for diabetic macular edema, OCS-02, a topical biologic candidate for dry eye disease, and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company was founded in 2016 and is headquartered in Zug, Switzerland.

M.D.Dr. Riad Sherif M.B.A.

Chief Financial OfficerMs. Sylvia Cheung

Chief Technology OfficerMs. Gudrun Bachmann Ph.D.

Ph.D.Prof. Bjorn Tackenberg M.D.

Chief Legal & Compliance OfficerMs. Katie A. Kazem

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

OCS

Oculis Holding AG

Upgrade your Finviz experience

All the Features.
Half the Price.